Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an “add on” to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.
- Cardiovascular diseases
- Hydroxymethylglutaryl-CoA reductase inhibitors
- Metabolic syndrome
- PPAR alpha
- Peroxisome proliferator-activated receptors
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism